We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
The National Institutes of Health (NIH) in the US has announced the initiation of two Phase III clinical trials analysing investigational monoclonal antibodies for treating people hospitalised with moderate Covid-19.